APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drug based on PARP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Drug based on PARP Inhibitor Industry Growth and Trends Forecast to 2032

2 January 202694 pages

Choose your research edition.

Industry ResearchCancer Drug based on PARP Inhibitor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drug based on PARP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Cancer Drug based on PARP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drug based on PARP Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drug based on PARP Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Drug based on PARP Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Drug based on PARP Inhibitor include Clovis Oncology, Zai Lab, AstraZeneca, GSK, Pfizer and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Drug based on PARP Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Drug based on PARP Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Drug based on PARP Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Drug based on PARP Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Cancer Drug based on PARP Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Drug based on PARP Inhibitor Market by Company

Clovis Oncology

Zai Lab

AstraZeneca

GSK

Pfizer

Merck & Co

Cancer Drug based on PARP Inhibitor Segment by Type

Talzenna

Rubraca

Zejula

Lynparza

Cancer Drug based on PARP Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

Cancer Drug based on PARP Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drug based on PARP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drug based on PARP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drug based on PARP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Cancer Drug based on PARP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Talzenna Table 2. Major Company of Rubraca Table 3. Major Company of Zejula Table 4. Major Company of Lynparza Table 5. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 7. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 8. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 9. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type (2021-2026) Table 10. Global Cancer Drug based on PARP Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 11. Global Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 12. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 13. Global Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 14. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type (2027-2032) Table 15. Global Cancer Drug based on PARP Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 16. North America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 17. North America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 19. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 23. Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 26. Cancer Drug based on PARP Inhibitor Industry Trends Table 27. Cancer Drug based on PARP Inhibitor Industry Drivers Table 28. Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges Table 29. Cancer Drug based on PARP Inhibitor Industry Restraints Table 30. Global Cancer Drug based on PARP Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Company (2021-2026) Table 32. Global Cancer Drug based on PARP Inhibitor Sales by Company (2021-2026) & (K Units) Table 33. Global Cancer Drug based on PARP Inhibitor Sales Share by Company (2021-2026) Table 34. Global Cancer Drug based on PARP Inhibitor Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Cancer Drug based on PARP Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Cancer Drug based on PARP Inhibitor Major Company Production Sites and Headquarters Table 37. Global Cancer Drug based on PARP Inhibitor Company, Product Type & Application Table 38. Global Cancer Drug based on PARP Inhibitor Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Cancer Drug based on PARP Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units) Table 43. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 44. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 45. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Region (2021-2026) Table 46. Global Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032) & (K Units) Table 48. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 49. Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 50. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Region (2027-2032) Table 51. Global Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 54. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 55. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 56. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application (2021-2026) Table 57. Global Cancer Drug based on PARP Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 58. Global Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 59. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 60. Global Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 61. Global Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application (2027-2032) Table 62. Global Cancer Drug based on PARP Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 63. North America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 64. North America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 66. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 70. Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 73. Clovis Oncology Company Information Table 74. Clovis Oncology Business Overview Table 75. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio Table 77. Clovis Oncology Recent Development Table 78. Zai Lab Company Information Table 79. Zai Lab Business Overview Table 80. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio Table 82. Zai Lab Recent Development Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio Table 87. AstraZeneca Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GSK Cancer Drug based on PARP Inhibitor Product Portfolio Table 92. GSK Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio Table 97. Pfizer Recent Development Table 98. Merck & Co Company Information Table 99. Merck & Co Business Overview Table 100. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio Table 102. Merck & Co Recent Development Table 103. North America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 104. North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 105. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 106. North America Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 107. North America Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 108. North America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Cancer Drug based on PARP Inhibitor Market Share by Country (2021-2026) Table 111. North America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Cancer Drug based on PARP Inhibitor Market Share Forecast by Country (2027-2032) Table 113. Europe Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 114. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 115. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 116. Europe Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 117. Europe Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 118. Europe Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Europe Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 120. Europe Cancer Drug based on PARP Inhibitor Market Share by Country (2021-2026) Table 121. Europe Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Europe Cancer Drug based on PARP Inhibitor Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 125. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 126. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 127. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Share by Country (2021-2026) Table 131. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Share Forecast by Country (2027-2032) Table 133. Latin America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 135. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 136. Latin America Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 137. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 138. Latin America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America Cancer Drug based on PARP Inhibitor Market Share by Country (2021-2026) Table 141. Latin America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America Cancer Drug based on PARP Inhibitor Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 145. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 146. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 147. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 148. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Share by Country (2021-2026) Table 151. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Share Forecast by Country (2027-2032) Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Cancer Drug based on PARP Inhibitor Distributors List Table 156. Cancer Drug based on PARP Inhibitor Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Cancer Drug based on PARP Inhibitor Image Figure 2. Global Cancer Drug based on PARP Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drug based on PARP Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Drug based on PARP Inhibitor Sales (2021-2032) & (K Units) Figure 5. Talzenna Image Figure 6. Global Talzenna Sales YoY Growth (2021-2032) & (K Units) Figure 7. Rubraca Image Figure 8. Global Rubraca Sales YoY Growth (2021-2032) & (K Units) Figure 9. Zejula Image Figure 10. Global Zejula Sales YoY Growth (2021-2032) & (K Units) Figure 11. Lynparza Image Figure 12. Global Lynparza Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Cancer Drug based on PARP Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Cancer Drug based on PARP Inhibitor Market Share by Type 2025 VS 2032 Figure 15. North America Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type in 2025 Figure 16. North America Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type in 2025 Figure 17. Europe Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type in 2025 Figure 18. Europe Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type in 2025 Figure 21. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Cancer Drug based on PARP Inhibitor Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Ovarian Cancer Image Figure 28. Global Ovarian Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 29. Breast Cancer Image Figure 30. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Cancer Drug based on PARP Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Cancer Drug based on PARP Inhibitor Market Share by Application 2025 VS 2032 Figure 35. North America Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application in 2025 Figure 36. North America Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application in 2025 Figure 37. Europe Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application in 2025 Figure 38. Europe Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application in 2025 Figure 41. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share in Value by Application in 2025 Figure 45. North America Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Cancer Drug based on PARP Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Cancer Drug based on PARP Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Cancer Drug based on PARP Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Cancer Drug based on PARP Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Cancer Drug based on PARP Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Cancer Drug based on PARP Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Cancer Drug based on PARP Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Cancer Drug based on PARP Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Cancer Drug based on PARP Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Cancer Drug based on PARP Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Cancer Drug based on PARP Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Cancer Drug based on PARP Inhibitor Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Cancer Drug based on PARP Inhibitor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Talzenna
  • Rubraca
  • Zejula
  • Lynparza
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Clovis Oncology
  • Zai Lab
  • AstraZeneca
  • GSK
  • Pfizer
  • Merck & Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Drug based on PARP Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Cancer Drug based on PARP Inhibitor Market by Type
  6. 1.3.1 Talzenna
  7. 1.3.2 Rubraca
  8. 1.3.3 Zejula
  9. 1.3.4 Lynparza
  10. 1.4 Global Cancer Drug based on PARP Inhibitor Market Size by Type
  11. 1.4.1 Global Cancer Drug based on PARP Inhibitor Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Cancer Drug based on PARP Inhibitor Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Cancer Drug based on PARP Inhibitor Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Cancer Drug based on PARP Inhibitor Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Cancer Drug based on PARP Inhibitor Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Cancer Drug based on PARP Inhibitor Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Cancer Drug based on PARP Inhibitor Industry Trends
  2. 2.2 Cancer Drug based on PARP Inhibitor Industry Drivers
  3. 2.3 Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges
  4. 2.4 Cancer Drug based on PARP Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Cancer Drug based on PARP Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by Cancer Drug based on PARP Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by Cancer Drug based on PARP Inhibitor Price (2021-2026)
  4. 3.4 Global Cancer Drug based on PARP Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Drug based on PARP Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global Cancer Drug based on PARP Inhibitor Company, Product Type & Application
  7. 3.7 Global Cancer Drug based on PARP Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Drug based on PARP Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Drug based on PARP Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Drug based on PARP Inhibitor Tier 1, Tier 2, and Tier 3
4 Cancer Drug based on PARP Inhibitor Regional Status and Outlook
  1. 4.1 Global Cancer Drug based on PARP Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Cancer Drug based on PARP Inhibitor Historic Market Size by Region
  3. 4.2.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Cancer Drug based on PARP Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Cancer Drug based on PARP Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Cancer Drug based on PARP Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global Cancer Drug based on PARP Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Cancer Drug based on PARP Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Cancer Drug based on PARP Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cancer Drug based on PARP Inhibitor by Application
  1. 5.1 Cancer Drug based on PARP Inhibitor Market by Application
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global Cancer Drug based on PARP Inhibitor Market Size by Application
  6. 5.2.1 Global Cancer Drug based on PARP Inhibitor Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Cancer Drug based on PARP Inhibitor Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Cancer Drug based on PARP Inhibitor Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Cancer Drug based on PARP Inhibitor Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Cancer Drug based on PARP Inhibitor Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Cancer Drug based on PARP Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Clovis Oncology
  2. 6.1.1 Clovis Oncology Company Information
  3. 6.1.2 Clovis Oncology Business Overview
  4. 6.1.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio
  6. 6.1.5 Clovis Oncology Recent Developments
  7. 6.2 Zai Lab
  8. 6.2.1 Zai Lab Company Information
  9. 6.2.2 Zai Lab Business Overview
  10. 6.2.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio
  12. 6.2.5 Zai Lab Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Merck & Co
  32. 6.6.1 Merck & Co Company Information
  33. 6.6.2 Merck & Co Business Overview
  34. 6.6.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio
  36. 6.6.5 Merck & Co Recent Developments
7 North America by Country
  1. 7.1 North America Cancer Drug based on PARP Inhibitor Sales by Country
  2. 7.1.1 North America Cancer Drug based on PARP Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America Cancer Drug based on PARP Inhibitor Market Size by Country
  6. 7.2.1 North America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Cancer Drug based on PARP Inhibitor Sales by Country
  2. 8.1.1 Europe Cancer Drug based on PARP Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
  6. 8.2.1 Europe Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Cancer Drug based on PARP Inhibitor Sales by Country
  2. 10.1.1 South America Cancer Drug based on PARP Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America Cancer Drug based on PARP Inhibitor Market Size by Country
  6. 10.2.1 South America Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Cancer Drug based on PARP Inhibitor Value Chain Analysis
  2. 12.1.1 Cancer Drug based on PARP Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Cancer Drug based on PARP Inhibitor Production Mode & Process
  7. 12.2 Cancer Drug based on PARP Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Cancer Drug based on PARP Inhibitor Distributors
  10. 12.2.3 Cancer Drug based on PARP Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst